CGeneTech(Suzhou,China) Co., Ltd.is a biotechnology company in the commercialization stage, with its core product, Class 1 innovative drug Shenggliptin, on the market. The company was founded in Suzhou Industrial Park in 2010, with a core team witdecades of experience in the entire lifecycle of international drugs, dedicated to the research and development and industrialization of high-quality and differentiated small molecule innovative drugs. With an integrated drug research and development technology platform and a diversified business perspective, the company has built a rich pipeline of innovative drugs covering hypoglycemic, anticancer, and autoimmune diseases.
In recent years, the new hypoglycemic drug DPP-4 inhibitors have become increasingly popular in China, and are praised by clinical doctors as the "smartest hypoglycemic drugs". The new generation of highly selective DPP-4 inhibitor Shenggliptin independently developed by the company in this field has been selected for the "Major New Drug Creation" special projects of the 12th and 13th Five Year Plans of the country. Currently, it has submitted an NDA (New Drug Listing Application) to the National Drug Administration and has been accepted. The results of the Phase 3 clinical trial showed that low doses can reach the predetermined trial endpoint, while the high-dose group can also demonstrate the safety of the drug well. The therapeutic effect of "half the dose, twice the effort" makes it expected to become the best hypoglycemic drug in the class. At the same time, the company has also carried out a comprehensive layout of oral drugs and derivative diseases around the global mainstream target of diabetes, in which the world's first SGLT-2/DPP-4 dual target inhibitor has been approved for clinical use to better treat diabetes and its derivative diseases.